Match!
Christian Weyer
Amylin Pharmaceuticals
120Publications
54H-index
15.2kCitations
Publications 106
Newest
#1T Velasquez (Boston Children's Hospital)H-Index: 1
#2G Mackey (BCM: Baylor College of Medicine)H-Index: 1
Last.Jorge Enrique Echeverri (Pontifical Xavierian University)H-Index: 3
view all 2151 authors...
1 CitationsSource
#1T VelasquezH-Index: 1
#2G MackeyH-Index: 1
view all 2152 authors...
#1T VelasquezH-Index: 1
#2G MackeyH-Index: 1
view all 2150 authors...
2 CitationsSource
#1Yehuda HandelsmanH-Index: 41
#2Elif A. Oral (UM: University of Michigan)H-Index: 26
Last.Christian Weyer (Amylin Pharmaceuticals)H-Index: 54
view all 14 authors...
48 CitationsSource
#1Jean ChanH-Index: 1
#2Karen LutzH-Index: 7
Last.Phillip GordenH-Index: 74
view all 7 authors...
Objective: To evaluate the long-term clinical effect of treatment with metreleptin (an analogue of human leptin) on glycemic and lipid abnormalities and markers of hepatic steatosis in patients with inherited or acquired lipodystrophy.Methods: Fifty-five patients (36 with generalized lipodystrophy and 19 with partial lipodystrophy) with at least 1 of 3 metabolic abnormalities (diabetes mellitus, fasting triglyceride level ≥200 mg/dL, and insulin resistance) and low leptin levels received subcuta...
89 CitationsSource
#1Jean L. ChanH-Index: 4
#2Karen LutzH-Index: 7
Last.Phillip GordenH-Index: 74
view all 7 authors...
Objective: To evaluate the long-term clinical effect of treatment with metreleptin (an analogue of human leptin) on glycemic and lipid abnormalities and markers of hepatic steatosis in patients with inherited or acquired lipodystrophy. Methods: Fifty-five patients (36 with generalized lipo dystrophy and 19 with partial lipodystrophy) with at least 1 of 3 metabolic abnormalities (diabetes mellitus, fasting triglyceride level ≥200 mg/dL, and insulin resistance) and low leptin levels received subcu...
#1James L. Trevaskis (Amylin Pharmaceuticals)H-Index: 23
#2Chunli Lei (Amylin Pharmaceuticals)H-Index: 3
Last.Jonathan D. Roth (Amylin Pharmaceuticals)H-Index: 21
view all 6 authors...
We have previously shown that combined amylin + leptin agonism elicits synergistic weight loss in diet-induced obese (DIO) rats. Here, we assessed the comparative efficacy of amylin, leptin, or amylin + leptin in the maintenance of amylin + leptin–mediated weight loss. DIO rats pretreated with the combination of rat amylin (50 µg/kg/day) and murine leptin (125 µg/kg/day) for 4 weeks were subsequently infused with either vehicle, amylin, leptin, or amylin + leptin for an additional 4 weeks. Food ...
70 CitationsSource
#1Jean L. Chan (Amylin Pharmaceuticals)H-Index: 4
#2Jonathan D. Roth (Amylin Pharmaceuticals)H-Index: 21
Last.Christian Weyer (Amylin Pharmaceuticals)H-Index: 54
view all 3 authors...
The discovery of leptin in 1994 was a seminal event in obesity research. It helped to establish that body weight is tightly regulated by a complex neurohormonal feedback system and that obesity should be viewed as a disorder with a strong biological basis rather than simply the result of poor lifestyle choices and lack of willpower. Leptin, secreted from adipocytes, acts as a prototypic long-term (tonic) adiposity signal. Although nonclinical and clinical studies have provided unequivocal eviden...
33 CitationsSource
#1Eric Ravussin (Pennington Biomedical Research Center)H-Index: 101
#2Steven R. Smith (Pennington Biomedical Research Center)H-Index: 71
Last.Christian Weyer (Amylin Pharmaceuticals)H-Index: 54
view all 8 authors...
The neurohormonal control of body weight involves a complex interplay between long-term adiposity signals (e.g., leptin), and short-term satiation signals (e.g., amylin). In diet-induced obese (DIO) rodents, amylin/leptin combination treatment led to marked, synergistic, fat-specific weight loss. To evaluate the weight-lowering effect of combined amylin/leptin agonism (with pramlintide/metreleptin) in human obesity, a 24-week, randomized, double-blind, active-drug-controlled, proof-of-concept st...
223 CitationsSource
It is well known that rapid-acting insulin analogues like insulin aspart (B28Asp) show a faster onset and a shorter duration of action than currently available U100 soluble insulin preparations. Since this effect is mainly due to a lower concentration of slow-absorbable hexamers, the metabolic profile of human insulin in lower concentration (e.g. U40 insulin) might be more similar to that of insulin aspart. Therefore, we compared the pharmacodynamic and pharmacokinetic properties of U40 soluble ...
16 CitationsSource
12345678910